Capital
Motley Fool says rising rates weigh more on Pfizer than AbbVie
The commentary cited Pfizer's 5.7% dividend yield against AbbVie's 2.4% and a 25-basis-point Fed increase in September 2026.
pharmaceuticals
Capital
The commentary cited Pfizer's 5.7% dividend yield against AbbVie's 2.4% and a 25-basis-point Fed increase in September 2026.